Delvenne, Aurore
Vandendriessche, Charysse
Gobom, Johan
Burgelman, Marlies
Dujardin, Pieter
De Nolf, Clint
Tijms, Betty M.
Teunissen, Charlotte E.
Schindler, Suzanne E.
Verhey, Frans
Ramakers, Inez
Martinez-Lage, Pablo
Tainta, Mikel
Vandenberghe, Rik
Schaeverbeke, Jolien
Engelborghs, Sebastiaan
De Roeck, Ellen
Popp, Julius
Peyratout, Gwendoline
Tsolaki, Magda
Freund-Levi, Yvonne
Lovestone, Simon
Streffer, Johannes
Bertram, Lars
Blennow, Kaj
Zetterberg, Henrik
Visser, Pieter Jelle
Vandenbroucke, Roosmarijn E.
Vos, Stephanie J. B.
Funding for this research was provided by:
Alzheimer Nederland (WE.15-2022-01)
Fonds Wetenschappelijk Onderzoek (1295223N)
EMIF-AD MBD
ZonMw (733050502)
Article History
Received: 15 April 2024
Accepted: 3 June 2024
First Online: 18 July 2024
Declarations
:
: Animal studies were conducted in compliance with governmental and EU guidelines and were approved by the ethical committee of the Faculty of Sciences, Ghent University, Belgium.All patients provided informed consent for research. All centers approved participation in this study after local medical ethics committee approval.
: Not applicable.
: Ms. Delvenne received funding from Alzheimer Nederland (grant number WE.15-2022-01). Dr. Schindler has served on advisory boards for Eisai. The institution of Dr. Vandenberghe has clinical trial agreements (RV as PI) with Alector, Biogen, Denali, EliLilly, J&J, UCB. The institution of Dr. Vandenberghe has consultancy agreements (RV as DSMB member) with AC Immune. Dr. Schaeverbeke is a senior postdoctoral fellow [12Y1623N] of FWO. Dr. Schaeverbeke receives funding from Stichting Alzheimer Onderzoek [SAO-FRA 2021/0022]. Dr. Popp served as a consultant and at advisory boards for the Nestlé Institute of Health Sciences, Ono Pharma, OM Pharma, Schwabe Pharma, Lilly, Roche, and Fujirebio Europe. All his disclosures are unrelated to the present work. The VD cohort was supported by grants from the Swiss National Research Foundation (SNF 320030_204886), Synapsis Foundation—Dementia Research Switzerland (Grant number 2017-PI01). Dr. Blennow has served as a consultant and at advisory boards for AC Immune, Acumen, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. Dr. Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Dr. Visser received funding from the European Commission, IMI 2 Joint Undertaking (JU), AMYPAD, grant n° 115952; European Commission, IMI 2 JU, RADAR-AD, grant n°806999; European Commission, IMI 2 JU, EPND, grant n°101034344. The IMI JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Dr. Visser received also funding from Zon-MW, Redefining Alzheimer's disease, grant n°733050824736; and Biogen (Amyloid biomarker study group). Grants were paid to the university. Dr. Vos received funding from ZonMW (SNAP VIMP grant n°7330505021), Stichting Adriana van Rinsum-Ponssen, and the EPND project, which received funding from the European Commision, IMI 2 Joint Undertaking (JU) under grant agreement n°101034344. The IMI JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. All others authors declare that they have no competing interests.